Brought to you by 
Recordati gets rights to Nymox's NX1207
21 Oct 2019
Executive Summary
Recordati Industria Chimia & Farmaceutica SPA has licensed exclusive European rights to Nymox Pharmaceutical Corp.’s (focused on the medical needs of the aging population) NX1207, a drug candidate in Phase III US trials for benign hyperplasia. The alliance includes Russia and the CIS, the Middle East, and the Maghreb area of North and South Africa (constituting 81 countries).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Recordati gets rights to Nymox's NX1207
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice